Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis

Cheng Han Ng, Jieling Xiao, Wen Hui Lim, Yip Han Chin, Jie Ning Yong, Darren Jun Hao Tan, Phoebe Tay, Nicholas Syn, Roger Foo, Mark Chan, Nicholas Chew, Eunice XX Tan, Daniel Q. Huang, Yock Young Dan, Nobuharu Tamaki, Mohammad Shadab Siddiqui, Arun J. Sanyal, Rohit Loomba, Mazen Noureddin, Mark D. Muthiah – 5 January 2022

Patient‐reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases

Marina Serper, Neehar D. Parikh, Grace Thiele, Nadia Ovchinsky, Shivang Mehta, Alexander Kuo, Chanda Ho, Fasiha Kanwal, Michael Volk, Sumeet K. Asrani, Marwan S. Ghabril, John R. Lake, Raphael B. Merriman, Timothy R. Morgan, Elliot B. Tapper – 5 January 2022

Development of Alcohol‐Associated Hepatitis Is Associated With Specific Changes in Gut‐Modified Bile Acids

Mark D. Muthiah, Ekaterina Smirnova, Puneet Puri, Naga Chalasani, Vijay H. Shah, Calvin Kiani, Stephanie Taylor, Faridoddin Mirshahi, Arun J. Sanyal – 3 January 2022 – The perturbations in bile acids (BAs) in alcohol‐associated hepatitis (AH) and its relationship to disease severity is not well defined. The aims of this study were to define (1) the effects of heavy alcohol consumption on BAs and related microbiome, (2) the additional changes with AH, and (3) the relationship of these changes to disease severity.

Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma

Yang Xie, Runzi Sun, Li Gao, Jibin Guan, Jingyuan Wang, Aaron Bell, Junjie Zhu, Min Zhang, Meishu Xu, Peipei Lu, Xinran Cai, Songrong Ren, Pengfei Xu, Satdarshan P. Monga, Xiaochao Ma, Da Yang, Yulan Liu, Binfeng Lu, Wen Xie – 2 January 2022 – The oxysterol receptor liver X receptor (LXR) is a nuclear receptor best known for its function in the regulation of lipid and cholesterol metabolism. LXRs, both the α and β isoforms, have been suggested as potential therapeutic targets for several cancer types.

Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD

Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Jeremy Broestl, Zobair Younossi, Nezam H. Afdhal, Michelle Lai – 29 December 2021 – Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, and its prevalence continues to rise. Fibrosis‐4 index (FIB‐4) has been shown to be a prognostic marker of liver‐related outcomes in patients with NAFLD. We analyzed data from TriNetX global federated research network, combining data on 30 million patients.

Subscribe to